<DOC>
	<DOCNO>NCT02824926</DOCNO>
	<brief_summary>This non-inferiority , Phase II , open-label , randomize , parallel trial evaluate efficacy safety new intervention ( Dapaconazole cream 2 % ) versus active control ( Ketoconazole cream 2 % ) patient Tinea Pedis . Study schedule comprises enrollment , treatment follow-up visit . Treatment period 14 day .</brief_summary>
	<brief_title>Clinical Trial Comparing BL123 Versus Ketoconazole Patients With Tinea Pedis</brief_title>
	<detailed_description>The study sample consist male female subject age 18 60 years-old , either single multiple Tinea Pedis lesion ( ) . Sixty ( 60 ) patient enrol , foot lesion ( ) consider one ( 1 ) sample . Therefore , patient bilateral lesion , one foot allocate investigational product ( Dapaconazole ) foot allocate active control ( Ketoconazole ) . Randomization determine foot ( right left ) treat Dapaconazole Ketoconazole .</detailed_description>
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Male female subject , age 18 60 yearsold ; Presence skin lesion ( ) characteristic Tinea Pedis , diagnosis confirm direct mycological exam ; Absence previous antifungic treatment current lesion ( ) study ; Absence significant disease , physician 's discretion , could impact subject 's participation trial , accord protocol requirement study evaluation : medical history , blood pressure heart rate , physical examination screen laboratory test ; Ability understand nature objective trial , include risk adverse event ; willingness cooperate researcher proceed accord study requirement , shall confirm Informed Consent Form signature . Known hypersensitivity ketoconazole chemically related compound ; history serious adverse reaction ; Current evidence clinically significant disease , physician 's discretion , prevent subject 's participation trial and/or expose subject risk normally expect ; Use medication , principal investigator 's discretion , might expose subject risk normally expect ; Screening laboratory test result show clinically relevant deviation , due potential risk , prevent participation trial , researcher 's discretion ; Drugs addiction , include alcohol ; Use previous treatment lesion ( ) study , accord principal investigator 's discretion , might interfere study objective ; Treatment , within 3 month trial , drug know wellestablished toxic potential major organ ; Participation experimental research administration experimental drug within 6 month trial ; Positive pregnancy test , labor miscarriage within 12 week study treatment ; Any condition , accord investigator 's discretion , prevent subject participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>